Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Teva launches AHZANTIVE biosimilar in Europe
Business product launch

Teva launches AHZANTIVE biosimilar in Europe

Analysis based on 8 articles · First reported Jun 04, 2026 · Last updated Jun 04, 2026

Sentiment
60
Attention
4
Articles
8
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The launch of AHZANTIVE by Sun Pharma is expected to positively impact Teva's stock due to portfolio expansion and market penetration in ophthalmology. Conversely, Regeneron Pharmaceuticals, the developer of the reference product Eylea, may face increased competition and potential revenue pressure from this biosimilar entry.

Pharmaceuticals Biotechnology
Event Summary

Sun Pharma announced the launch of AHZANTIVE (aflibercept), a biosimilar to Eylea, in Europe. This launch, which began in May 2026 across markets including France, Germany, Spain, and The Netherlands, strengthens Teva's biosimilars portfolio and expands its presence in ophthalmology. AHZANTIVE received European Commission approval in 2025 for treating serious retinal diseases like Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO). The launch is part of Teva's Pivot to Growth strategy and follows a semi-exclusive commercialization agreement with Klinge Biopharma GmbH and Formycon AG.

Key Actions
90 Sun Pharma launched biosimilar
70 European Union approved biosimilar
60 Sun Pharma signed commercialization agreement Klinge Biopharma GmbH
60 Sun Pharma signed commercialization agreement Formycon AG
Entities Involved
stock
Sun Pharma
Sun Pharma launched AHZANTIVE, a biosimilar to Eylea, in Europe, expanding its biosimilars portfolio and presence in ophthalmology, aligning with its Pivot to Growth strategy.
Importance 100 Sentiment 70
priv
Klinge Biopharma GmbH
Klinge Biopharma GmbH has a semi-exclusive commercialization agreement with Sun Pharma for AHZANTIVE in major parts of Europe and Israel.
Importance 60 Sentiment 50
stock
Formycon AG
Formycon AG has a semi-exclusive commercialization agreement with Sun Pharma for AHZANTIVE in major parts of Europe and Israel.
Importance 60 Sentiment 50
stock
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is the developer of Eylea, the reference product for Sun Pharma' newly launched biosimilar AHZANTIVE, which could lead to increased competition.
Importance 40 Sentiment -30
alliance
European Union
The European Commission approved AHZANTIVE in 2025, allowing its launch in European markets.
Importance 30 Sentiment 0
cnt
France
France is one of the European markets where Sun Pharma launched AHZANTIVE.
Importance 20 Sentiment 0
cnt
Germany
Germany is one of the European markets where Sun Pharma launched AHZANTIVE.
Importance 20 Sentiment 0
cnt
Spain
Spain is one of the European markets where Sun Pharma launched AHZANTIVE.
Importance 20 Sentiment 0
cnt
Netherlands
The Netherlands is one of the European markets where Sun Pharma launched AHZANTIVE.
Importance 20 Sentiment 0
cnt
Israel
Israel is a market where Sun Pharma has a commercialization agreement for AHZANTIVE.
Importance 20 Sentiment 0
per
Yolanda Tibbe
Yolanda Tibbe, Global Head of Biosimilars at Sun Pharma, commented on the importance of biosimilars for sustainable healthcare systems.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.